8-11-14-eicosatrienoic-acid and Acute-Kidney-Injury

8-11-14-eicosatrienoic-acid has been researched along with Acute-Kidney-Injury* in 4 studies

Other Studies

4 other study(ies) available for 8-11-14-eicosatrienoic-acid and Acute-Kidney-Injury

ArticleYear
A synthetic epoxyeicosatrienoic acid analogue prevents the initiation of ischemic acute kidney injury.
    Acta physiologica (Oxford, England), 2019, Volume: 227, Issue:2

    Imbalances in cytochrome P450 (CYP)-dependent eicosanoid formation may play a central role in ischemic acute kidney injury (AKI). We reported previously that inhibition of 20-hydroxyeicosatetraenoic acid (20-HETE) action ameliorated ischemia/reperfusion (I/R)-induced AKI in rats. Now we tested the hypothesis that enhancement of epoxyeicosatrienoic acid (EET) actions may counteract the detrimental effects of 20-HETE and prevent the initiation of AKI.. Male Lewis rats underwent right nephrectomy and ischemia was induced by 45 min clamping of the left renal pedicle followed by up to 48 h of reperfusion. Circulating CYP-eicosanoid profiles were compared in patients who underwent cardiac surgery with (n = 21) and without (n = 38) developing postoperative AKI.. Ischemia induced an about eightfold increase of renal 20-HETE levels, whereas free EETs were not accumulated. To compensate for this imbalance, a synthetic 14,15-EET analogue was administered by intrarenal infusion before ischemia. The EET analogue improved renal reoxygenation as monitored by in vivo parametric MRI during the initial 2 h reperfusion phase. The EET analogue improved PI3K- as well as mTORC2-dependent rephosphorylation of Akt, induced inactivation of GSK-3β, reduced the development of tubular apoptosis and attenuated inflammatory cell infiltration. The EET analogue also significantly alleviated the I/R-induced drop in creatinine clearance. Patients developing postoperative AKI featured increased preoperative 20-HETE and 8,9-EET levels.. Pharmacological interventions targeting the CYP-eicosanoid pathway could offer promising new options for AKI prevention. Individual differences in CYP-eicosanoid formation may contribute to the risk of developing AKI in clinical settings.

    Topics: 8,11,14-Eicosatrienoic Acid; Acute Kidney Injury; Animals; Cardiac Surgical Procedures; Fatty Acids; Humans; Hydroxyeicosatetraenoic Acids; Ischemia; Kidney; Male; Postoperative Complications; Rats; Rats, Inbred Lew; Reperfusion Injury; Signal Transduction

2019
Protection against acute kidney injury is afforded by a 14,15-epoxy-eicosatrienoic acid (EET) analog-A potential druggable pathway.
    Acta physiologica (Oxford, England), 2019, Volume: 227, Issue:2

    Topics: 8,11,14-Eicosatrienoic Acid; Acute Kidney Injury; Fatty Acids, Unsaturated; Humans

2019
Epoxide metabolites of arachidonate and docosahexaenoate function conversely in acute kidney injury involved in GSK3β signaling.
    Proceedings of the National Academy of Sciences of the United States of America, 2017, 11-21, Volume: 114, Issue:47

    Acute kidney injury (AKI) causes severe morbidity and mortality for which new therapeutic strategies are needed. Docosahexaenoic acid (DHA), arachidonic acid (ARA), and their metabolites have various effects in kidney injury, but their molecular mechanisms are largely unknown. Here, we report that 14 (15)-epoxyeicosatrienoic acid [14 (15)-EET] and 19 (20)-epoxydocosapentaenoic acid [19 (20)-EDP], the major epoxide metabolites of ARA and DHA, respectively, have contradictory effects on kidney injury in a murine model of ischemia/reperfusion (I/R)-caused AKI. Specifically, 14 (15)-EET mitigated while 19 (20)-EDP exacerbated I/R kidney injury. Manipulation of the endogenous 19 (20)-EDP or 14 (15)-EET by alteration of their degradation or biosynthesis with selective inhibitors resulted in anticipated effects. These observations are supported by renal histological analysis, plasma levels of creatinine and urea nitrogen, and renal NGAL. The 14 (15)-EET significantly reversed the I/R-caused reduction in glycogen synthase kinase 3β (GSK3β) phosphorylation in murine kidney, dose-dependently inhibited the hypoxia/reoxygenation (H/R)-caused apoptosis of murine renal tubular epithelial cells (mRTECs), and reversed the H/R-caused reduction in GSK3β phosphorylation in mRTECs. In contrast, 19 (20)-EDP dose-dependently promoted H/R-caused apoptosis and worsened the reduction in GSK3β phosphorylation in mRTECs. In addition, 19 (20)-EDP was more metabolically stable than 14 (15)-EET in vivo and in vitro. Overall, these epoxide metabolites of ARA and DHA function conversely in I/R-AKI, possibly through their largely different metabolic stability and their opposite effects in modulation of H/R-caused RTEC apoptosis and GSK3β phosphorylation. This study provides AKI patients with promising therapeutic strategies and clinical cautions.

    Topics: 8,11,14-Eicosatrienoic Acid; Acute Kidney Injury; Animals; Blood Urea Nitrogen; Creatinine; Docosahexaenoic Acids; Gene Expression Regulation; Glycogen Synthase Kinase 3 beta; Humans; Kidney Tubules; Lipocalin-2; Male; Mice; Mice, Inbred C57BL; Phosphorylation; Reperfusion Injury; Signal Transduction; Survival Analysis

2017
Attenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor κB signaling.
    The Journal of pharmacology and experimental therapeutics, 2012, Volume: 341, Issue:3

    Acute kidney injury is associated with a significant inflammatory response that has been the target of renoprotection strategies. Epoxyeicosatrienoic acids (EETs) are anti-inflammatory cytochrome P450-derived eicosanoids that are abundantly produced in the kidney and metabolized by soluble epoxide hydrolase (sEH; Ephx2) to less active dihydroxyeicosatrienoic acids. Genetic disruption of Ephx2 and chemical inhibition of sEH were used to test whether the anti-inflammatory effects of EETs, and other lipid epoxide substrates of sEH, afford protection against cisplatin-induced nephrotoxicity. EET hydrolysis was significantly reduced in Ephx2(-/-) mice and was associated with an attenuation of cisplatin-induced increases in serum urea nitrogen and creatinine levels. Histological evidence of renal tubular damage and neutrophil infiltration was also reduced in the Ephx2(-/-) mice. Likewise, cisplatin had no effect on renal function, neutrophil infiltration, or tubular structure and integrity in mice treated with the potent sEH inhibitor 1-adamantan-1-yl-3-(1-methylsulfonyl-piperidin-4-yl-urea) (AR9273). Consistent with the ability of EETs to interfere with nuclear factor-κB (NF-κB) signaling, the observed renoprotection was associated with attenuation of renal NF-κB activity and corresponding decreases in the expression of tumor necrosis factor (TNF) α, TNF receptor (TNFR) 1, TNFR2, and intercellular adhesive molecule-1 before the detection of tubular injury. These data suggest that EETs or other fatty acid epoxides can attenuate cisplatin-induced kidney injury and sEH inhibition is a novel renoprotective strategy.

    Topics: 8,11,14-Eicosatrienoic Acid; Acute Kidney Injury; Adamantane; Animals; Antineoplastic Agents; Blood Urea Nitrogen; Cisplatin; Creatinine; Enzyme Inhibitors; Epoxide Hydrolases; Intercellular Adhesion Molecule-1; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; NF-kappa B; Real-Time Polymerase Chain Reaction; Signal Transduction; Tumor Necrosis Factor-alpha

2012